Disclosures under Regulation 62 of the SEBI LODR
Details of requirements mentioned in sub-regulation 1 of Regulation 62 of Listing Regulation
Notice of the Board meeting where financial results shall be discussed
- Notice of 111th Board Meeting_August 13, 2024_Approval of FS_MaxLife
- Notice of 110th Board Meeting_May 7, 2024_Approval of FS_MaxLife
- Notice for the 109th Statutory Board Meeting_Approval of FS_December 31,2023
- Notice for the 107th Statutory Board Meeting_Approval of FS_September 30, 2023
- Notice for the 106th Statutory Board Meeting_Max Life
- Notice for the 105th Statutory Board Meeting
- Notice for the 104th Statutory Board Meeting_Approval of FS_January 31, 2023
- Notice for the 103rd Statutory Board Meeting_Approval of FS_October 19, 2022
- Notice for the 102nd Statutory Board Meeting_Approval of FS_August 1, 2022
- Notice for the 101st Statutory Board Meeting_Approval of FS_May 10, 2022
- Notice for the 100th Statutory Board Meeting_Approval of FS_January 28, 2022
- Notice for the 99th Statutory Board Meeting_Approval of FS_November 9, 2021
- Notice for the 97th Statutory Board Meeting_Approval of FS_August 10, 2021
Disclosures/ Submissions/ Reports filed by the Company to the Stock exchange
- NewspaperPublicationOfFinancialResults_Q1FY25_MaxLife
- IntimationUnderRegulation51_ChangeInSecretarialAuditors_MaxLife
- AuditedFinancialStatements_QE30June2024_MaxLife_SEBILODR
- DisclosureUnderSEBILODR_13082024_MaxLife
- IntimationToNSE_Reg50(1)_SEBILODR_MaxLife
- CertificateOfInterestPaymentUnderReg57_SEBILODR_02Aug2024_MaxLife
- DisclosureUnderPara2OfChapterXIV_NCSoperationalFramework_MaxLife_02Aug2024
- StatementOfInvestorGrievances_MaxLife_QE30June2024
- IntimationUnderReg60(2)ofSEBI(LODR)_RecordDate_InterestPayment_Aug2024
- DisclosureUnderReg7(1)ofSEBI(LODR)_30June2024_MaxLife
- DisclosureUnderReg6(1)ofSEBI(LODR)_QE30June2024_MaxLife
- NewspaperPublicationOfFinancialResults_Q4FY24_MaxLife
- SubmissionOfAnnualReportFY24_Reg53(2)_SEBILODR_MaxLife
- AuditedFinancialResults_QEandFYE31March2024_MaxLife_SEBI(LODR)
- IntimationToNSE_Reg50(2)_SEBILODR_MaxLife_May2024
- Proceedingsof24thAGMofMaxLife_7May2024_Reg51(2)_SEBILODR
- IntimationUnderReg51_ChangeInDirectors_MLIC
- IntimationToNSE_Reg50(1)_SEBILODR_MaxLife
- CertificateUnderReg61(4)ofSEBI(LODR)_MaxLife_31March2024
- ComplianceCertificate_Reg3(5)&Reg3(6)ofSEBI(PIT)Regulations_31Mar2024
- DisclosureUnderChapterXIV_NCSoperationalFramework_SEBI_31Mar2024
- ComplianceCertificateUnderReg7(3)_SEBI(LODR)_31March2024
- DisclosureUnderReg6(1)ofSEBI(LODR)_MaxLife_QE31March2024
- DisclosureUnderReg7(1)ofSEBI(LODR)_MaxLife_31March2024
- IntimationtoNSE_Reg51(2)_SEBI(LODR)_April122024
- StatementOfInvestorGreivances_MaxLife_QE31March2024
- HYstatementUnderChVIIIofNCSOperationalCircular_31March2024
- DisclosureToStockExchange_ApprovalFromCCI_MaxLife
- IntimationToNSE_Para9.1OfChXIOfNCSoperationalcircular_31Mar2024_MaxLife
- DisclosureOnNewsItem_MaxLife
- NewspaperPublicationOfFinancialResults_Q3FY24_MaxLife
- IntimationUnderReg51_ChangeInDirectors_SEBILODR_MLIC
- ProceedigsOfEGM_6February2024_Reg51(2)_SEBI(LODR)_MaxLife
- DisclosureUnderExtantSEBI(LODR)Regulations_IRDAIapprovalOnCapitalinfusion
- AuditedFinancialResults_SEBI(LODR)_QE31December2023_MaxLife
- IntimationToNSE_Reg50(1)_SEBILODR_MaxLife
- StatementOfInvestorGreivances_MaxLife_QE31December2023
- DisclosureUnderReg7(1)oftheSEBI(LODR)_MaxLife_31December2023
- DisclosureUnderReg6(1)ofSEBI(LODR)_MaxLife_QE31December2023
- ComplianceCertificate_Reg3(5)&Reg3(6)ofSEBI(PIT)Regulations_31December2023
- DisclosureToNSE_SEBI(LODR)_ChangeInDirectors_MaxLife_4Dec2023
- DisclosureUnderSEBI(LODR)_MaxLife_CessationOfOfficeOfMrVViswanand
- NewspaperPublicationOfFinancialResults_Q2FY24_MaxLife
- AuditedFinancialResults_SEBI(LODR)_QE30Sept2023_MaxLife
- IntimationTo NSE_Reg50(1)_SEBILODR_MaxLife
- DisclosureUnderReg7(1)oftheSEBI(LODR)_MaxLife_30September2023
- StatementUnderChapterVIII_NCSOperationalCircular_30Sept2023
- CertificateUnder57(5)_SEBILODR2015_MaxLife_QE30September2023
- ComplianceCertificate_Reg3(5)&Reg3(6)ofSEBI(PIT)Regulations_30September2023
- DisclosureUnderReg6ofSEBI(LODR)MaxLife_QE30September2023
- StatementOfInvestorGreivances_MaxLife_QE30September2023
- IntimationToNSE_Reg51(2)_SEBI(LODR)_MaxLife_28Sept2023
- NSEDisclosure_ReappointmentOfMrPrashantTripathy_MLIC
- NewspaperPublicationOfFinancialResults_Q1FY24_MaxLife
- DisclosureUnderSEBILODRRegulations_MaxLife_InfusionOfCapital
- OutcomesOfBoardMeeting_Reg51_SEBILODR_9August2023_MaxLife
- CertificateOfInterestPaymentUnderReg57(1) _02Aug2023_MaxLife
- DisclosureToNSEunderPara2ofChapterXIV_NCSoperationalFramework_MaxLife
- IntimationToNSE_Reg50(1)_SEBILODR_MaxLife
- DisclosureUnderReg7(1)oftheSEBI(LODR)_MaxLife_30June2023
- ComplianceCertificate_Reg 3(5)and 3(6)ofSEBI(PIT)Regulations_30June2023
- DisclosureUnderReg6ofSEBI(LODR)MaxLifeQE_30June2023
- StatementOfInvestorGreivances_MaxLife_30June2023
- IntimationToNSEunderRegulation60(2)OfSEBILODR_MaxLife
- AuditedFinancialResultsAndSecurityCover_March31,2023_MaxLife_NSEDisclosure
- SubmissionOfAnnualReportFY23_Reg 53(2)_SEBILODR_MaxLife
- IntimationToNSE_Reg50(2)_SEBILODR_MaxLife
- IntimationToNSEReg51SEBI(LODR)MaxLifeMay122023
- NewspaperPublicationOfFinancialResults_Q4FY23_MaxLife
- DetailsOfIncrementalBorrowings_FY2023_ChapterXIIofSEBINCSoperationalcircular_MLIC
- IntimationToNSE_Reg50(1)_SEBILODR_MaxLife
- CertificateUnderRegulation61OfSEBILODRRegulations
- DisclosureUnderPara2OfChapterXIVOfNCSPperationalFrameworkMLIC
- Initial Disclosure to NSE_LC Under Chapter XII_SEBI Operational Circular_Max Life
- Compliance Certificate Under Clause7(3)ofSEBILODR_MaxLife_YE March 31 2023
- Compliance Certificate_Reg 3(5) & 3(6)of_SEBI(PIT) Regulations_March 31 2023
- DisclosureUnderReg7(1)oftheSEBILODRMaxLifeQEMarch312023
- DisclosureUnderReg6oftheSEBILODRMaxLifeQEMarch312023
- Intmation to NSE_Para 9.1 of Chapter XI of Ncs Operational Circular_March31, 2023
- StatementOfInvestorGrievances_Max Life_March 312023
- StatementUnderSEBINCSOperationCircularMaxLifeMarch312023
- NewspaperpublicationOfQ3FY23ResultsMaxLife
- AuditedFinancialResultsAndSecurityCover_Dec312022_MaxLife_NSEDisclosure
- IntimationToNSE_Reg50_SEBILODR_MaxLife_January232023
- Compliance Certificate_Regulation 3(5) 3(6)_SEBI (PIT) Regulations_December 31 2022
- SubmissionOfRestatedAOAToNSE_January92023
- IntimationToNSE_Reg51(2)_SEBILODR_MaxLife_January2023
- DisclosureUnderReg7oftheSEBILODRMaxLifeQEDecember312022
- DisclosureUnderReg6oftheSEBILODRMaxLifeDecember312022
- StatementOfInvestorGrievances_MaxLife_December312022
- IntimationtoNSE_TransferStakeOfMaxLifeByMSItoMFSL_Nov282022
- DisclosureUnder54(3)_Max Life
- NewspapaerPublicationOfQ2FY23Results_MaxLife
- AuditedFinancialResults_September302022_MaxLife_SEBILODR
- IntimationtoNSE_Reg50_SEBILODR_MaxLife_September2022
- Compliance Certificate_Regulation 3(5), 3(6)_SEBI (PIT) Regulations 2015_18.11.2022
- DisclosureUnderReg6and7oftheSEBILODRMaxLife_QESeptember302022
- StatementOfInvestorGrievances_MaxLife_September302022
- StatementUnderSEBINCSOperationCircularMaxLifeSeptember302022_Revised
- CertificateUnder57(5)_SEBILODR2015_MaxLife_Revised
- IntimationtoNSE_PressReleaseRegardingReceiptOfCOBbyMLPFM_MaxLife
- NewspaperPublicationOfQ1FY23Results_MaxLife
- CertificateOfInterestPaymentUnderReg57(1)_SEBILODR_MaxLife
- QuarterlyAuditedFinancialResults_QE30June2022_MaxLife
- SubmissionToNSE_Para2_ChapterXIVofNCSoperationalframework_MaxLife
- IntimationToNSE_Reg50_SEBILODR_MaxLife_June2022
- DisclosureUnderReg6and7oftheSEBILODRMaxLife_QE_june30_2022
- StatementOfInvestorGrievances_MaxLife_June302022
- IntimationtoNSEunderRegulation60(2)ofSEBILODR_MaxLife
- IntimationtoNSEunderRegulation57(4)OfSEBILODR_MaxLife
- NewspaperPublicationOfQ4AndFY22Results_MaxLife
- AssetCoverUnder54_MaxLife
- AuditedFinancialResults_March312022_MaxLife_SEBILODR
- AnnualReport_Reg53(2)_SEBILODR_MaxLife_10May2022
- IntimationToNSE_Reg51(2)_SEBILODR_MaxLife_May2022
- IntimationToNSE_Reg50(1)_SEBILODR_MaxLife_May2022
- IntimationToNSE_Reg50(2)_SEBILODR_MaxLife_May2022
- Initial Disclosure to NSE_LC_SEBI circular dated Nov 26, 2018
- Compliance Certificate Under Clause7(3)ofSEBILODR_MaxLife
- Disclosure Under Reg6and7 of the SEBILODR_MaxLife
- StatementOfInvestorGrievances_Max Life_March312022
- StatementUnderSEBINCSOperationCircularMaxLifeMarch312022
- IntimationtoNSEForResignationofDyChiefFinancialOfficerMaxLife
- Intimation to NSE_Para 9.1 of Chapter XI of NCS operational framework_Ma
- IntimationForIncorporationOfWhollyOwnedSubsdiary
- Intimation To NSE_Reg50 SEBI LODR MaxLife January 28-01-2022
- Quarterly Financial Results December-31-2021 MaxLife
- Newspaper Publication Of Q3 FY22 Results MaxLife
- Intimation to NSE Regarding Reg6and7 of SEBI LODR MaxLife December-2021
- Statement of Investor Grievances MaxLife December 31 2021
- Certificate on Asset Coverage Ratio_September 30, 2021
- Intimation to NSE_Reg 6 and 7_SEBI LODR_MaxLife
- Intimation to NSE_Reg50_SEBI LODR_MaxLife_Nov 2, 2021
- Newspaper publication of Q2FY22 Results_MaxLife
- Statement for Utilisation of Proceeds_MaxLife_Sept 30, 2021
- Statement of Investor grievances_MaxLife_Sept 30, 2021
- Statement under SEBI circular dated August 10, 2021
Credit Rating
Subordinated Debt Rating
Credit rating of subordinated debt reflects the degree of safety regarding timely servicing of financial obligations.
Rating Agency |
Rating |
Rating Date |
CRISIL |
CRISIL AA+ / Stable |
JUN-24 |
ICRA |
ICRA AA+ / Stable |
JUN-24 |
CRISIL |
CRISIL AA+ / Stable |
JUL-23 |
ICRA |
ICRA AA+ / Stable |
JUL-23 |
CRISIL |
CRISIL AA+ / Stable |
JUL-22 |
ICRA |
ICRA AA+ / Stable |
JUL-22 |
CRISIL |
CRISIL AA+ / Stable |
JUL-21 |
ICRA |
ICRA AA+ / Stable |
JUL-21 |
Email & Contact Information of the Designated Officials who are responsible for Assisting and Handling Investor Grievances
For investor grievances, please contact:
Anurag Chauhan
Company Secretary and Compliance Officer
Email: investorgrievance@maxlifeinsurance.com
Telephone: +91 124 412 1500
Email and Contact Information of the Debenture Trustee
IDBI Trusteeship Services Limited
Address: Asian Building, Ground Floor,
17 R. Kamani Marg, Ballard Estate
Mumbai- 400 001
Phone: 022 40807000
Email: itsl@idbitrustee.com
Website: www.idbitrustee.com